Want to see FR:ALMDT full AI Analyst Report?
ALMDT Stock Chart & Stats
€4.06
€0.03(0.63%)
At close: 4:00 PM EDT
€4.06
€0.03(0.63%)
Day’s Range― - ―
52-Week Range€1.79 - €7.27
Previous CloseN/A
Volume15.31K
Average Volume (3M)465.96K
Market Cap
€197.65M
Enterprise Value€180.92
Total Cash (Recent Filing)€18.41M
Total Debt (Recent Filing)€21.76M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding48,719,810
10 Day Avg. Volume398,206
30 Day Avg. Volume465,957
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio-9.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€25.43M
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumA 21.5% revenue increase in 2025 indicates growing commercial traction in imaging analytics and trial services. Durable project-based revenues from clinical trials can scale with additional study wins, enabling potential operating leverage as fixed costs are spread across higher volumes over the medium term.
Specialized Imaging AI NicheA specialist position in imaging analytics and AI-driven biomarkers aligns with structural growth in quantitative imaging adoption by biopharma. High technical barriers, validation requirements and integration into trial workflows create durable competitive advantages and the potential for sticky, multi-year contracts with sponsors.
Relatively Stable Asset BaseRelatively stable total assets provide operational continuity for service delivery and R&D while commercial expansion proceeds. This stability supports execution on trial contracts and platform development, reducing risk of short-term operational disruption even as capital structure and profitability are addressed.
Bears Say
Negative EquityPersistent negative shareholders' equity materially weakens financial flexibility and heightens refinancing and dilution risk. Over a 2–6 month horizon this constrains the company's ability to invest, secure favorable credit terms, or absorb setbacks, making external funding likely and costly.
Consistent Operating Cash BurnRepeated negative operating cash flow signals structural cash burn and reliance on external financing to sustain operations. This undermines the firm's ability to fund sales, validation and R&D activities internally, increasing execution risk on contract wins and slowing margin recovery without new capital.
Negative Gross Profit & Deep LossesNegative gross profit indicates the core business fails to cover direct costs, suggesting pricing, cost structure, or mix issues. Such structural unprofitability limits the ability of revenue growth to translate into margin improvement and requires fundamental changes to restore unit economics and sustainable profitability.
Median Technologies News
ALMDT FAQ
What was Median Technologies’s price range in the past 12 months?
Median Technologies lowest stock price was €1.79 and its highest was €7.27 in the past 12 months.
What is Median Technologies’s market cap?
Median Technologies’s market cap is €197.65M.
When is Median Technologies’s upcoming earnings report date?
Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 77 days.
How were Median Technologies’s earnings last quarter?
Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Median Technologies overvalued?
According to Wall Street analysts Median Technologies’s price is currently Overvalued.
Does Median Technologies pay dividends?
Median Technologies does not currently pay dividends.
What is Median Technologies’s EPS estimate?
Median Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Median Technologies have?
Median Technologies has 48,719,810 shares outstanding.
What happened to Median Technologies’s price movement after its last earnings report?
Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.957%.
Which hedge fund is a major shareholder of Median Technologies?
Currently, no hedge funds are holding shares in FR:ALMDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Median Technologies
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―